Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML.

Nature communications - 14 Nov 2024

Wu Yitian, Zhang Shuai, Feng Ru, Xiao Kangming, Wang Ting, Bai Jiefei, Zhou Xiaoyu, Wang Yuji, Dai Peng, Liu Hui, Wu Lucia Ruojia

Abstract excerpt

Relapse is one of the major challenges in clinical treatment of acute myeloid leukemia (AML). Though minimal residual disease (MRD) monitoring plays a crucial role in quantitative assessment of the disease, molecular MRD analysis has been mainly limited to patients diagnosed with gene fusions and NPM1 mutations. Here, we report a longitudinal ultra-sensitive mutation burden (UMB) monitoring strategy for accurate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Frequency
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Longitudinal Studies

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Recurrence

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 39543210
DOI: 10.1038/s41467-024-54254-6
PMCID: PMC11564880

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML.PMID 39543210Read ↗

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.Semantic proximity Read ↗

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read ↗

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.Semantic proximity Read ↗

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.Semantic proximity Read ↗

Prognostic and Therapeutic Implications of Measurable Residual Disease Detection Across Hematologic Malignancies: Clinical Impact on Relapse Prediction and Survival OutcomesSemantic proximity Read ↗

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemiaSemantic proximity Read ↗

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AMLSemantic proximity Read ↗

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemiaSemantic proximity Read ↗

Calibration-free NGS Quantitation of Mutations below 0.01% VAFSemantic proximity Read ↗

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and PerspectivesSemantic proximity Read ↗

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Semantic proximity Read ↗

Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.